Durvalumab following definitive chemoradiotherapy among patients with stage III NSCLC in the Thai population: a real-world, multicenter observational study
Durvalumab following definitive CRT demonstrated promising outcomes and was well-tolerated in this real-world study. These findings support the utilization of durvalumab for enhancing outcomes in patients with unresectable LA-NSCLC within Asian populations.
Authors
- Archara Supavavej (ORCID: https://orcid.org/0000-0002-3270-5553)
- Kunlatida Maneenil (ORCID: https://orcid.org/0009-0004-0194-4860)
- Krittiya Korphaisarn (ORCID: https://orcid.org/0000-0001-5739-0175)
- Piyada Sitthideatphaiboon (ORCID: https://orcid.org/0000-0003-2098-1646)
- Piyarat Limpawittayakul (ORCID: https://orcid.org/0000-0002-0057-6769)
- Virote Sriuranpong (ORCID: https://orcid.org/0000-0001-8787-5026)
- Naiyarat Prasongsook (ORCID: https://orcid.org/0000-0002-0634-2541)
- Luangyot Thongthieang
- Hataiwan Ratanabunjerdkul (ORCID: https://orcid.org/0009-0008-2129-2221)
- Thanyanan Reungwetwattana (ORCID: https://orcid.org/0000-0002-3147-7640)
- Sureerat Jaruhathai
- Chawalit Chayangsu (ORCID: https://orcid.org/0000-0002-2743-0532)
- Thatthan Suksombooncharoen (ORCID: https://orcid.org/0000-0003-1996-3387)
- Chirawadee Sathitruangsak
Institutions
- Thammasat University (TH)
- Prince of Songkla University (TH)
- Siriraj Hospital (TH)
- Khon Kaen University (TH)
- King Chulalongkorn Memorial Hospital (TH)
- Thammasat University Hospital (TH)
- Phramongkutklao Hospital (TH)
- Chulabhorn Hospital (TH)
- Police General Hospital (TH)
- Ramathibodi Hospital (TH)
- Surin Hospital (TH)
- Chiang Mai University (TH)
- Rangsit University (TH)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fonc.2025.1647385
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca